Andrea Treyer
0000-0002-4533-7761
3 papers found
Refreshing results…
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation
Missing publications? Search for publications with a matching author name.